IL-2Rα, combined with measurement of regenerating islet-derived protein 3 alpha or REG3α [a GVHD target organ-specific damage biomarkers (122)] and ST2 enabled the development of a validated predictive algorithm (Mount Sinai Acute GVHD International Consortium or MAGIC), based on ST2 and REG3α concentrations after one week of systemic glucocorticoid treatment, to predict life-threatening GVHD and NRM (98). This evidence concerns the gene REG3A and acute graft versus host disease.